Oral Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Quality - Proactive or Reactive (A Consumer Perspective) (#33)

Grant Mundell 1 2
  1. Consumer, Sydney, NSW, Australia
  2. Deutsche Bank, Lane Cove, NSW, Australia

I was fortunate to receive a high quality of care and feel proactive and reactive approaches can both work depending on different patient circumstances. In my view, the involvement of a multi-disciplinary team (MDT) was crucial to the success of my care. Neuroendocrine cancer is a less common cancer, it is a misdiagnosed cancer and poorly understood by the medical community. A combination of specialists consistently reviewing my case ensured that the right decisions (whether they be proactive to attack my illness or reactive my changing conditions) were made. This was effectively communicated back to me through my oncologist and was supplemented by the nursing staff and my patient Cancer Care Coordinator. Having a combination of proactive and reactive care meant that while different treatments were being discussed, they were only finally decided upon when either my circumstances changed or the team became confident that they were the best course of action. The quality of care was endorsed by the high level of trust I had in the medical team that supported me. Being treated by an MDT is efficient and much safer way of treating a patient, especially one like me that has a rare/uncommon cancer, as opposed to potentially having one oncologist that knows very little about these cancers and having that one person with little or no knowledge make decisions on his/her own with no consultation to experts in that field that could potentially impact the length of survival and quality of life of a patient.